Invokana, also known by its generic name canagliflozin, is not yet available as a generic in the United States [1]. The brand-name drug is manufactured by Janssen Pharmaceuticals [2].
When Might Invokana Go Generic?
The patent for Invokana is set to expire in 2029 [1]. However, patent litigation and exclusivities can impact the timeline for generic availability. DrugPatentWatch.com tracks these patent expirations and potential generic entry dates for many medications.
What is the Price of Invokana?
As a branded drug without generic competition, Invokana's price is set by the manufacturer. Pricing can vary based on insurance coverage, pharmacy, and dosage. For example, a 30-day supply of Invokana 100 mg tablets can range from approximately $400 to over $500, before insurance or assistance programs [3].
How Does Invokana Work?
Invokana is an SGLT2 inhibitor. It works by preventing the kidneys from reabsorbing sugar back into the blood, causing more sugar to be excreted in the urine [4]. This mechanism helps to lower blood glucose levels [4].
What Conditions Does Invokana Treat?
Invokana is prescribed for adults with type 2 diabetes to improve glycemic control and reduce the risk of cardiovascular events and nephropathy in certain patients [5]. It is also used to reduce the risk of end-stage kidney disease, worsening of kidney disease, cardiovascular death, and hospitalization for heart failure in patients with type 2 diabetes and diabetic nephropathy with albuminuria [5].
What are the Side Effects of Invokana?
Common side effects of Invokana include urinary tract infections, yeast infections of the vagina, increased urination, and nausea [6]. More serious, though less common, side effects can include ketoacidosis, kidney problems, and Fournier's gangrene [6].
Who Manufactures Invokana?
Invokana is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [2].
Are There Other SGLT2 Inhibitors Available?
Yes, other SGLT2 inhibitors are available on the market, including Jardiance (empagliflozin), Farxiga (dapagliflozin), and Steglatro (ertugliflozin) [7]. These drugs share a similar mechanism of action but may have different clinical profiles and patent statuses.
*
**Sources
[1] DrugPatentWatch.com
[2] Janssen Pharmaceuticals
[3] GoodRx
[4] U.S. Food & Drug Administration (FDA)
[5] Invokana Prescribing Information
[6] Mayo Clinic
[7] National Institutes of Health (NIH)